Sales & Marketing

The benefits of adopting a humanized approach to healthcare provider marketing extend across the healthcare spectrum, enhancing engagement rates, brand loyalty, and marketing ROI, while also driving better outcomes for patients.

In an interview with Pharm Exec Associate Editor Don Tracy, Fady Boctor, President, Chief Commercial Officer, Petros Pharmaceuticals talks about the recent availability of Opill as an over-the-counter (OTC) contraceptive.

How life sciences companies can design an effective operating model for DOL engagements.

How consumer goods marketing approaches can support pharmaceutical and life sciences companies in their growth this year.

In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, talks about what's coming marketing with the use of AI.

In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, talks about how he has successfully combined cutting-edge technologies with traditional marketing approaches in his past ventures.

In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, explains utilizing generative AI for rapid content creation and how AI-driven automation of that content distribution has increased visibility.

Investigation aimed to discern whether the differences in antibiotic prescribing between direct-to-consumer telemedicine appointments and primary care physician telemedicine appointments were due to the care modality or the context of the care.

As part of the partnership, BeiGene will serve as a sponsor at LLS events.

In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, discusses how AI could have helped address past challenges.

Webinar Date/Time: Tue, Apr 23, 2024 1:00 PM EDT

In this Pharmaceutical Executive interview, Jill Jaroch, Senior Director, Women’s Health & Urology Marketing at Astellas, discusses the decision to continue VEOZAH's presence during the big game, the inspiration and message behind the commercial, and if Taylor Swift played a factor in their decision making

The winner will receive $1 million and the chance to partner with a major industry leader.

Eli Lilly continues to emphasize the potential harm that could come with using GLP-1 receptor agonists for off-label purposes.

Chases discusses how traditional media platforms still coexist with digital platforms and how this impacts promotion.

The partnership has the goal of improving patient education and treatment directions.

Rebranding aims to align company with its parent company and other subsidiaries.

Commentary cites lower control over health plan costs and the potential bias for prescribing drugs through influence from drug manufacturers.

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract Gen-Z.

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses their recent data and research about some massive behavioral shifts occurring across Gen-Z

Letter emphasizes the need to protect children from potentially harmful medical advice spread on social media.

Researchers highlight several benefits and concerns associated with the launch of direct-to-consumer models for GLP-1 receptor agonists.

The campaign, that started in 2012, is back with seven new faces—many of which included messaging about the harms of menthol cigarettes.

Treatment aims to reduce the risk of finger or toe amputation due to frostbite.

Webinar Date/Time: Thu, Mar 28, 2024 2:00 PM EDT

According to the study conducted by Technavio, North America will contribute to 37% of the expected growth.

Joint venture aims to submit an Investigational New Drug application to the FDA by early next year for treatment that targets solid tumors.

The company has struggled to supply the drug to patients due to overwhelming popularity.

Rusfertide is currently in a pivotal Phase III clinical trial as a potential first-in-class treatment for polycythemia vera.

Aduhelm (aducanumab-avwa) was granted accelerated approval by the FDA in June 2021 despite misgivings from the agency's Peripheral and Central Nervous System Drugs Advisory Committee.